New Hampshire Governor Vetoes Medical Marijuana Greenhouse Bill

New Hampshire’s medical cannabis growers will stay locked inside costly, fully enclosed warehouses after Gov. Kelly Ayotte rejected a bipartisan bill that would have let them move some production into greenhouses — a change supporters said would cut energy bills and lower prices for patients.

Ayotte, a Republican, vetoed the measure on June 12, 2026, in a two-sentence statement that left no room for negotiation. “I do not support expanding the cultivation of marijuana in our state,” she wrote. It was one of three bills she vetoed that week.

What the bill would have changed

Under New Hampshire’s therapeutic cannabis program, created in 2013, the nonprofit alternative treatment centers that supply the state’s patients must grow indoors, in secure, fully enclosed facilities. The vetoed bill would have let each center apply to the state Department of Health and Human Services to run a single greenhouse cultivation site, either alongside its existing grow or at a separate location.

Greenhouses trade artificial lighting and around-the-clock climate control for sunlight, which sharply reduces the electricity demand that makes indoor cannabis one of the most energy-intensive crops to produce. The sponsors built that cost argument directly into the bill. A center seeking approval would have had to submit a plan showing how greenhouse growing would lower its energy costs and reduce prices for registered patients, then report each year on whether it delivered. The department would have written rules on siting and security, and any greenhouse would have remained subject to local zoning and community input.

Why the supply structure matters

The stakes are tied to how tightly New Hampshire controls supply. A small group of nonprofit alternative treatment centers — the only operations licensed to cultivate, process, and sell therapeutic cannabis in the state — run seven dispensaries serving more than 12,000 registered patients. When those growers carry high production costs, patients feel it at the register. Operators and the program’s medical oversight board have argued for years that expensive indoor cultivation prices medicine out of reach for some of the people the program was built to serve. New Hampshire’s tightly capped, vertically integrated license structure leaves patients with few alternatives, as a look at the state’s cannabis licensing requirements makes clear.

That dynamic runs against the direction several states have taken this year. Iowa, for example, doubled its medical dispensary cap, and Kentucky added more than a dozen qualifying conditions to its program.

A familiar veto

The bill cleared both chambers on voice votes, carried by bipartisan sponsorship led by Sen. Howard Pearl, a Loudon Republican, and endorsed unanimously by the House committee that reviewed it. That breadth of support did not move the governor, who has built a consistent record against loosening the state’s cannabis laws.

It is also the second time in two years a New Hampshire governor has killed a nearly identical greenhouse proposal. Then-Gov. Chris Sununu vetoed a similar bill in 2024, faulting it for thin detail on safety, security, and siting. The 2026 version handed those specifics to state regulators and local officials, but Ayotte’s objection was broader: she opposes expanding cultivation at all, not the fine print of how a greenhouse would be secured.

Her resistance is consistent with a wider stance. Ayotte campaigned against adult-use legalization and has repeatedly said she will veto any bill that creates a recreational market, leaving New Hampshire the only New England state without one. Governors elsewhere have reached for the same tool to slow cannabis expansion — Virginia’s governor blocked a retail-sales measure this year, a veto that hemp and cannabis groups framed as a policy reset.

What happens next

The veto may not be the last word. New Hampshire lawmakers can override it with a two-thirds vote in both the House and Senate, and the Legislature is expected to take up the three vetoed bills when it reconvenes later in 2026. But passage by voice vote, where no individual positions are recorded, is a weak predictor of whether two-thirds of members will go on record to override a governor of their own party. For the state’s growers and the patients who buy from them, that vote will decide whether cheaper, greenhouse-grown medicine stays off the table for at least another year.